Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Visionstate Announces Deals in Canada and the US, Highlights Growing Opportunities (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BIOAGE Labs Inc BIOA

Healthcare Biotechnology
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product candidate, azelaprag, is an orally available small molecule agonist of the apelin receptor (APJ) that was observed to promote metabolism and prevent muscle atrophy during bed rest in a Phase Ib clinical trial. It has initiated a Phase II trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has the potential as an oral regimen to reduce weight loss and improve body composition in patients on obesity therapy with incretin drugs. It is also developing orally available small molecule brain penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. Its preclinical programs, based on novel insights from the Company’s discovery platform built on human longevity data, address key pathways in metabolic aging.


NDAQ:BIOA - Post by User

BIOAGE Labs Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(294)
•••
Post by whytestockson Dec 11, 2024 2:45pm
11 Views
Post# 36357245

Bronstein, Gewirtz & Grossman, LLC Announces an Investigatio

Bronstein, Gewirtz & Grossman, LLC Announces an Investigatio
BREAKING NEWS: $BIOA Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioAge Labs, Inc. (BIOA) and Encourages Stockholders to Learn More About the InvestigationNEW YORK, NY / ACCESSWIRE / December 11, 2024 / Bronstein, Gewirtz &amp; Grossman, LLC is investigating potential claims on behalf of purchasers of BioAge Labs, Inc. ("BioAge Labs" or "the Company") (NASDAQ:BIOA). Investors who purchased BioAge Labs securities are encouraged to obtain additional...BIOA - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioAge Labs, Inc. (BIOA) and Encourages Stockholders to Learn More About the Investigation

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities